Febuxostat Indications and Usage

Primary Indications

Febuxostat is indicated for the treatment of chronic hyperuricemia in patients with gout where urate deposition has already occurred, according to the American College of Rheumatology 1
Febuxostat is a non-purine selective inhibitor of xanthine oxidase used for urate-lowering therapy (ULT) in patients with gout, as recommended by the European League Against Rheumatism 2, 3
Febuxostat is particularly indicated in patients with recurrent gout flares, tophi, urate arthropathy, or uric acid renal stones, as suggested by the American College of Rheumatology 4, 5, 6

Febuxostat is preferred in patients with moderate to severe renal impairment (eGFR <60 ml/min), according to the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 5, 7
Febuxostat can be considered when allopurinol is not tolerated or contraindicated, especially in patients with a history of allopurinol hypersensitivity syndrome or the HLA-B*5801 allele, as recommended by the American College of Medical Genetics and Genomics 4, 8, 9

Febuxostat is available in 40 mg and 80 mg doses, and treatment should be initiated at a low dose (40 mg/day) with subsequent titration to achieve target serum urate levels, as suggested by the European League Against Rheumatism 2, 3, 5, 6
Target serum urate level should be <6 mg/dL for most patients, but a lower target (<5 mg/dL) may be recommended for patients with severe gout, according to the American College of Rheumatology 4, 5, 6

Febuxostat 80 mg/day is more effective than allopurinol 300 mg/day at decreasing serum urate levels, as shown in clinical trials published in the Annals of Internal Medicine 2, 10
No major differences in outcomes or total adverse events were found between allopurinol 300 mg/day and febuxostat 40 mg/day, according to the European League Against Rheumatism 2, 10

The American College of Rheumatology conditionally recommends switching to an alternative urate-lowering therapy for patients taking febuxostat with a history of cardiovascular disease or new cardiovascular events, due to the increased risk of cardiovascular events 7
Prophylaxis against acute gout flares should be provided when initiating febuxostat, typically with colchicine or low-dose NSAIDs if not contraindicated, as recommended by the American College of Rheumatology 5, 6

The European League Against Rheumatism (EULAR) recommends febuxostat as second-line therapy after allopurinol optimization, for patients who fail to achieve target serum urate levels 11
The American College of Rheumatology recommends either allopurinol or febuxostat as first-line pharmacologic urate-lowering therapy, without preferential recommendation of one over the other 12, 13

The American College of Rheumatology suggests monitoring serum uric acid every 2-5 weeks during titration, then every 6 months once target achieved, when using febuxostat 13

Febuxostat functions as a urate-lowering therapy (ULT) that requires continuous, long-term use to maintain therapeutic benefit, specifically indicated for chronic hyperuricemia in conditions where urate deposition has already occurred, including patients with recurrent gout flares, tophi, urate arthropathy, or uric acid renal stones 14, 15

Febuxostat works by selectively inhibiting xanthine oxidase to reduce serum uric acid production, which requires continuous administration to maintain target serum urate levels, with the therapeutic goal of durably improving signs and symptoms of gout through sustained reduction of serum urate 14, 15
The therapeutic goal is to durably improve signs and symptoms of gout through sustained reduction of serum urate, not to treat acute flares 14

Evidence shows that longer-term urate-lowering therapy (>1 year) reduces gout flares, confirming its role as maintenance therapy, according to the American College of Physicians 16, 17

Febuxostat does NOT treat acute gout attacks, and high-quality evidence shows that urate-lowering therapy does not reduce the risk for gout attacks within the first 6 months of initiation, as recommended by the American College of Physicians 16, 17
The American College of Physicians recommends that febuxostat should not be used to treat acute gout attacks, but rather as a long-term strategy to prevent future attacks through sustained uric acid reduction 16, 17